免疫检查点LAG-3在肿瘤免疫中的研究进展  

Research progress of immune checkpoint LAG-3 in tumor immunity

作　　者：韩杰 李晋虎 刘晓东[1] 慕伟[1] 范益民[1] Han Jie;Li Jinhu;Liu Xiaodong;Mu Wei;Fan Yimin(Department of Neurosurgery,the First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一医院神经外科,太原030001

出　　处：《中华神经创伤外科电子杂志》2021年第3期182-186,共5页Chinese Journal Of Neurotraumatic Surgery：Electronic Edition

基　　金：山西省应用基础研究计划面上青年基金(201901D211478)。

摘　　要：淋巴细胞激活基因3(LAG-3)是体内重要的抑制性免疫检查点,通过抑制各种淋巴细胞激活和细胞因子分泌,从而确保免疫稳态。然而肿瘤细胞常利用这一点发生免疫逃逸,目前LAG-3已被发现在多种类型的肿瘤浸润淋巴细胞中高表达。本文将从LAG-3的基因、结构、功能以及LAG-3和程序性死亡受体1的双重阻断在肿瘤免疫治疗中的作用进行阐述,以期为肿瘤的免疫治疗提供进一步的参考。Lymphocyte activating gene 3(LAG-3)is an important inhibitory immune checkpoint in vivo that ensures immune homeostasis by inhibiting various lymphocyte activation and cytokine secretion.However,tumor cells often use this to undergo immune escape and LAG-3 have currently been found to be highly expressed in many types of tumor-infiltrating lymphocytes.In this paper,the gene,structure and function of LAG-3 and the role of dual blockade of LAG-3 and programmed deathreceptor-1 in cancer immunotherapy will be described in order to provide further reference for cancer immunotherapy.

关 键 词：免疫检查点 淋巴细胞激活基因3 程序性死亡受体1 癌症免疫疗法 

分 类 号：R730.51[医药卫生—肿瘤]